These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23775968)

  • 61. Prognostic Implication of Longitudinal Changes of Left Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis.
    Bak M; Kim D; Choi JO; Kim K; Kim SJ; Jeon ES
    Front Cardiovasc Med; 2022; 9():904878. PubMed ID: 35811735
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Primary light chain amyloidosis onset with acquired FX deficiency: a case report and literature review].
    Wei C; Feng J; Zhu TN
    Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):680-682. PubMed ID: 32942824
    [No Abstract]   [Full Text] [Related]  

  • 63. Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure.
    Tahir UA; Doros G; Kim JS; Connors LH; Seldin DC; Sam F
    Sci Rep; 2019 Jun; 9(1):8552. PubMed ID: 31189919
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
    Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [How I treat immunoglobulin light chain amyloido-sis].
    Du J; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):469-474. PubMed ID: 28655088
    [No Abstract]   [Full Text] [Related]  

  • 66. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
    Sanchorawala V; Palladini G; Kukreti V; Zonder JA; Cohen AD; Seldin DC; Dispenzieri A; Jaccard A; Schönland SO; Berg D; Yang H; Gupta N; Hui AM; Comenzo RL; Merlini G
    Blood; 2017 Aug; 130(5):597-605. PubMed ID: 28550039
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [The consensus of the diagnosis and treatment of primary light chain amyloidosis in China (2016 version)].
    ;
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):742-746. PubMed ID: 27719714
    [No Abstract]   [Full Text] [Related]  

  • 68. Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.
    Venner CP; Gillmore JD; Sachchithanantham S; Mahmood S; Lane T; Foard D; Roussel M; Rannigan L; Gibbs SDj; Pinney JH; Whelan CJ; Lachmann HJ; Hawkins PN; Wechalekar AD
    Haematologica; 2014 Dec; 99(12):e260-3. PubMed ID: 25193959
    [No Abstract]   [Full Text] [Related]  

  • 69. Update on treatment of light chain amyloidosis.
    Mahmood S; Palladini G; Sanchorawala V; Wechalekar A
    Haematologica; 2014 Feb; 99(2):209-21. PubMed ID: 24497558
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.
    Girnius S; Seldin DC; Meier-Ewert HK; Sloan JM; Quillen K; Ruberg FL; Berk JL; Doros G; Sanchorawala V
    Bone Marrow Transplant; 2014 Mar; 49(3):434-9. PubMed ID: 24317129
    [TBL] [Abstract][Full Text] [Related]  

  • 71. New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation.
    D'Souza A; Huang J; Hari P
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):768-770. PubMed ID: 26743343
    [TBL] [Abstract][Full Text] [Related]  

  • 72. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
    Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
    J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [TBL] [Abstract][Full Text] [Related]  

  • 75. New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation.
    Girnius S; Seldin DC; Cibeira MT; Sanchorawala V
    J Clin Oncol; 2013 Jul; 31(21):2749-50. PubMed ID: 23775968
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.